Tumor Necrosis Factor Blocker [EPC]

831377 reported adverse events

Drugs of this class: ADALIMUMAB-ATTO INFLIXIMAB GOLIMUMAB CERTOLIZUMAB PEGOL ETANERCEPT INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	97955
1	INJECTION SITE PAIN	57976
2	ARTHRALGIA	55639
3	OFF LABEL USE	53824
4	PAIN	50399
5	RHEUMATOID ARTHRITIS	48778
6	INJECTION SITE ERYTHEMA	41598
7	FATIGUE	38045
8	CONDITION AGGRAVATED	33561
9	HEADACHE	30591

See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	HUMAN ANTICHIMERIC ANTIBODY POSITIVE	292	0.9766
1	INJECTION SITE RECALL REACTION	483	0.9718
2	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	3479	0.9357
3	SWOLLEN JOINT COUNT INCREASED	835	0.8892
4	RHEUMATOID FACTOR POSITIVE	2940	0.8750
5	RED BLOOD CELL SEDIMENTATION RATE ABNORMAL	1711	0.8342
6	RHEUMATIC FEVER	1081	0.8177
7	PEMPHIGUS	6214	0.8019
8	C-REACTIVE PROTEIN ABNORMAL	2947	0.7753
9	HAND DEFORMITY	6297	0.7271

See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]